Amgen to buy Horizon Therapeutics in $26.4B deal

Dec 11, 2022, 1:37 PM | Updated: Dec 12, 2022, 7:38 am
FILE - This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2...

FILE - This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2014. Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion. (AP Photo/Mark J. Terrill, File)

(AP Photo/Mark J. Terrill, File)

Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics.

The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market.

The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.

Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.

U.S. regulators approved Tepezza in early 2020 as the first treatment for thyroid eye disease. The drug’s sales more than doubled last year to $1.67 billion. That’s about half of the company’s total sales of $3.23 billion.

Amgen leaders told analysts on a Monday morning conference call that they intend to expand the drug’s use globally. Scientists also are working to develop and easier-to-use injectable version of the drug, which is given by IV.

Amgen Chairman and CEO Robert Bradway said the deal gives his company a “strong platform” to expand into rare disease treatments, with many Horizon drugs still early in their life cycle.

Horizon also makes Krystexxa for uncontrolled gout. Sales of that treatment grew 39% last year to $565.5 million. Amgen officials said they expect their company’s long-standing history of working with rheumatologists will help that treatment’s sales grow.

Horizon also has a pipeline of additional potential treatments in mid-stage clinical testing and a possible therapy for the autoimmune disease myasthenia gravis in late-stage testing.

Amgen is facing competition for some of its key products like its autoimmune disease treatment Enbrel, so a Horizon takeover makes strategic sense, Mizuho Securities USA analyst Salim Syed said in a research note. He also said Horizon’s presence in Ireland, which has lower corporate tax rates than the United States, could help Amgen cut its tax bill.

Horizon said late last month that it had started “highly preliminary discussions” about an acquisition with three potential suitors: Amgen, the French drugmaker Sanofi, and Johnson & Johnson’s Janssen division.

Amgen had confirmed discussions were taking place and said that any offer it made for Horizon likely would be in cash.

The deal laid out Monday represents a premium of 48% to Horizon’s closing price of $78.76 before it made that late-November announcement.

Amgen said it expects the deal, which has an enterprise value of about $28.3 billion, to close in the first half of next year.

Horizon’s stock price jumped more than 14% after markets opened Monday. They had already soared about 30% since the late November announcement.

Shares of Amgen Inc., based northwest of Los Angeles in Thousand Oaks, California, fell about 1%, while broader indexes climbed slightly.

___

Follow Tom Murphy on Twitter: https://twitter.com/thpmurphy

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Paul Njoroge, right, points to photos of his wife and three children that were killed in the 2019 c...
Associated Press

Boeing pleads not guilty in case over deadly Max crashes

FORT WORTH, Texas (AP) — Boeing pleaded not guilty Thursday to a charge that it misled regulators who approved its 737 Max, the plane that was involved in two crashes that killed 346 people. Family members of passengers who died gave emotional testimony, calling for criminal prosecution of top Boeing officials. The families are trying […]
22 hours ago
Associated Press

Thursday’s Scores

BOYS PREP BASKETBALL= Concordia Christian 60, Pacific Christian Academy 18 Elma 50, Montesano 34 Forks 52, Crescent 45 Franklin Pierce 72, Fife 54 Oakville 84, Lake Quinault 28 Puget Sound Adventist 47, Gem State Adventist, Idaho 34 Rogue Valley Adventist, Ore. 73, Walla Walla Academy 62 Washington 81, Steilacoom 68 ___ Some high school basketball […]
22 hours ago
Associated Press

Thursday’s Scores

GIRLS PREP BASKETBALL= Clarkston 72, West Valley (Spokane) 35 Crosspoint Academy 40, Sound Christian 27 Grace Academy 41, Tulalip Heritage 21 Lynden Christian 67, Blaine 25 Mossyrock 60, Pe Ell 18 Northwest Yeshiva 46, Rainier Christian 12 Orcas Island 62, Concrete 23 Quilcene 26, Northwest Christian (Lacey) 12 Tumwater 44, W. F. West 39 Walla […]
22 hours ago
abortion Capital gains tax Olympia meeting legislature abortion...
Associated Press

Washington lawmakers hear testimony on 7 abortion bills

Abortion rights proposals have been front and center in Olympia, Washington, this week as state lawmakers heard hours of public testimony on seven proposals that would reinforce abortion access.
22 hours ago
FILE - A pumpjack as seen on Wednesday, March 30, 2022, in Tatum, New Mexico. For the second time t...
Associated Press

House GOP seeks new restrictions on use of US oil stockpile

WASHINGTON (AP) — For the second time this month, House Republicans are seeking to restrict presidential use of the nation’s emergency oil stockpile — a proposal that has already drawn a White House veto threat. A GOP bill set for a vote Friday would require the government to offset any non-emergency withdrawals from the Strategic […]
22 hours ago
Associated Press

Today in History: JAN 27, Auschwitz and Birkenau liberated

Today in History Today is Friday, Jan. 27, the 27th day of 2022. There are 338 days left in the year. Today’s Highlight in History: On Jan. 27, 1967, astronauts Virgil I. “Gus” Grissom, Edward H. White and Roger B. Chaffee died in a flash fire during a test aboard their Apollo spacecraft. On this […]
22 hours ago

Sponsored Articles

safety from crime...

As crime increases, our safety measures must too

It's easy to be accused of fearmongering regarding crime, but Seattle residents might have good reason to be concerned for their safety.
Comcast Ready for Business Fund...
Ilona Lohrey | President and CEO, GSBA

GSBA is closing the disparity gap with Ready for Business Fund

GSBA, Comcast, and other partners are working to address disparities in access to financial resources with the Ready for Business fund.
SHIBA WA...

Medicare open enrollment is here and SHIBA can help!

The SHIBA program – part of the Office of the Insurance Commissioner – is ready to help with your Medicare open enrollment decisions.
Lake Washington Windows...

Choosing Best Windows for Your Home

Lake Washington Windows and Doors is a local window dealer offering the exclusive Leak Armor installation.
Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Amgen to buy Horizon Therapeutics in $26.4B deal